Navigation Links
Halozyme Reports First Quarter 2012 Financial Results
Date:5/7/2012

ater convenience to patients versus the traditional IV method due to its less invasive administration route and quicker administration time (5 minutes versus 30 – 90 minutes).  
  • Roche reiterated their intent to file the Line Extension Application of subcutaneous MabThera® (rituxumab with rHuPH20) to the EMA this year for the treatment of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Follicular Lymphoma.
  • Announced positive data with ViroPharma regarding a Phase 2 SC trial of Cinryze® (C1 esterase inhibitor [human]) in combination with rHuPH20, in patients with hereditary angioedema. Presented at the American Academy of Allergy Asthma & Immunology, the study demonstrated that SC co-administration of Cinryze with rHuPH20 was well tolerated and resulted in sustained physiologically relevant C1 INH functional concentrations.
  • Updated the Hylenex® recombinant (hyaluronidase human injection) label to include instructions for pre-administration of the enzyme in advance of other injected or subcutaneously infused drugs, and information from non-clinical studies that provide further data on the safety profile of Hylenex.
  • First Quarter 2012 Financial ResultsThe net loss for the first quarter of 2012 was $15.1 million, or $0.14 per share, compared with a net loss for the first quarter of 2011 of $9.6 million, or $0.10 per share.

  • Revenues for the first quarter of 2012 were $7.4 million, compared to $7.5 million for the first quarter of 2011. Revenues in the first quarter of 2012 primarily consisted of a milestone payment from Roche of $4 million and research and development reimbursements from partners.
  • Research and development expenses for the first quarter of 2012 were $15.9 million, compared with $13.8 million for the first quarter of 2011, primarily due to an increase in manufacturing activities and compensation costs, partially offset by a decrease in clinical trial act
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
    3. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
    4. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
    5. Halozyme Announces Proposed Public Offering of Common Stock
    6. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
    7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    8. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
    9. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
    10. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
    11. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... , July 31, 2014 Hovione ... Ireland has successfully passed a pre-approval inspection by ... inspection, carried out by the FDA Consumer Safety Officer, Ms. ... started on 21 st July and concluded on the ... compliant with the principles and guidelines of Good Manufacturing Practices ...
    (Date:7/31/2014)... 31, 2014 Catylix, Inc. ( ... Milpitas, California ) announced today the ... commercialize new fluorination products and related chemistry. ... from the use of substituents that are chemically ... polarity to improve binding and bioavailability. Fluorinated functional ...
    (Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
    Breaking Medicine Technology:Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
    ... in a Single Pill to Target Three Major ... Next Phase of Development, ABBOTT PARK, Ill. and ... will advance the development of,Abbott,s next-generation fenofibrate ABT-335 and ... Phase III,clinical trials. The single pill would target all ...
    ... Aug. 30 ,Palatin Technologies, Inc. (Amex: PTN ... announced today that they have delayed plans for ... a first in class,melanocortin agonist drug candidate, for ... follows responses from representatives of,the U.S. Food and ...
    Cached Medicine Technology:Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination 2Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination 3King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction 2
    (Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars ... 7788 East Horn Road in Lake Leelanau. Joining the Northern ... Cellars is the 25th winery along the trail. The winery ... tour events, making its trail event debut during the Harvest ... Owners David and Faye Mathia opened the boutique winery in ...
    (Date:7/31/2014)... July 31, 2014 Ce-Classes.com has announced ... course for healthcare professionals, a Systematic Review of ... material published in the International Journal of Clinical and ... in response to a need to have accurate information ... the best treatment possible. The material provides a ...
    (Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
    (Date:7/31/2014)... (PRWEB) July 31, 2014 The vineyards are ... the upcoming harvest. And, to celebrate, folks are gearing up ... Sunday, September 6 and 7, 2014 along the Leelanau ... an optional walk or run through the vineyards start-ing at ... Suttons Bay. A unique course between rows of grapevines offers ...
    (Date:7/31/2014)... United Theological Seminary is pleased to welcome ... and Peter J. Bellini. Both began their teaching duties ... a Director of Non-Degree Programs, Mark Abbott, who begins ... Donne, Assistant Professor of New Testament, received a Ph.D. ... Second Temple Judaism, and Greek courses. His research interests ...
    Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2
    ... type of disease, that requires insulin injections daily. Researchers ... this disease. Some medical research centers in the U.S. ... I diabetes by transplanting insulin-producing islet cells combined with ... live normal lives without insulin. , ...
    ... come up with a new technique of removing cancerous ... their hands and a special camera and instuments. This ... in significantly less time than the standard laproscopic procedure. ... of the American Urological Association by surgeons from the ...
    ... new gene which has the ability to slow down ... millions of people each year, and luckily tthe discovery ... the cancer of the colon, prostate,pancreas,brain and bowel. ... to stunt the cancer by starving the tumour ...
    ... from Mayo Clinic brings more choice in eating heath food// ... into any weight loss diets that restrict choices in food. ... the report that talks of sustainable eating habits that help ... weight requires a long-term commitment to making lifestyle changes. However, ...
    ... Researchers from UCLA had reported in the recent issue ... sleep suffer from loss of brain cells due to ... apnea, the person stops breathing during the sleep when ... in the brain as preB?tzinger complex (preB?tC), which is ...
    ... and its function has always left man dazzled for ... key factors// have been identified that could answer the ... babies and hence help treat prematurity. ,Identification ... brain damage repair in neurological diseases like multiple sclerosis ...
    Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Making operation and recovery time shorter 2Health News:New Healthy Weight Program Makes Healthy Eating More Interesting 2Health News:Sleep Apnea Related To Death And Loss Of Brain Cells 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
    ... Final Flexion Wraps restore full PIP joint ... when lost due to arthritic changes. Unparalleled ... material hugs the finger to prevent slipping ... motion. One size. Sold in packages of ...
    One splint does it all....
    ... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
    ... braces are designed to provide comfortable stabilization ... and versatile, ROM braces are an easy ... The braces are extremely patient-friendly, too. , ... hinges that allow you to restrict extension ...
    Medicine Products: